Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

NCT04280471 | Withdrawn Phase 1 DMC FDA Drug

• 2 other identifiers: 19-001736NCI-2020-00211
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This phase I trial studies the side effects of using an investigational procedure (fecal microbiota transplantation \[FMT\]) in treating patients with severe acute gut graft-versus-host-disease. The purpose of a fecal microbiota transplantation is to use feces from a healthy human donor to replace the abnormal gut bacteria in the recipient. One of the side effects of a stem cell transplant is the development of graft-versus-host disease (GvHD) in several organs including gut. GvHD is caused by the donated bone marrow or peripheral blood cells recognizing the recipient's body as foreign and attacking it. Acute gut GvHD is one of the leading causes of death after transplant. Recently, studies have shown that patients with reduced intestinal bacterial diversity in their stool during acute gut GvHD have higher overall mortality rates. The information learned from this study may offer FMT as a promising therapy for the treatment of severe acute gut graft-versus-host-disease.

Conditions

Acute Graft Versus Host Disease; Gastrointestinal Tract Acute Graft Versus Host Disease; Severe Gastrointestinal Tract Acute Graft Versus Host Disease; Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease

Keywords

Gut GvHD; FMT

Outcome Measures

Primary Outcomes (1)

• Incidence of adverse events

  For safety evaluation, episodes of microbial bloodstream infection attributed to fecal microbiota transplantation (FMT) within the first 7 days after start of each FMT administration. For tolerability evaluation, at least 60% of subjects able to ingest 50% of one dose of FMT without grade 3 or higher adverse events (AEs) within the first 7 days post-FMT. Subjects will be monitored via assessment of gut graft versus host disease (GvHD) staging and adverse events will be performed bi-weekly for the first 4 weeks after the first dose of FMT, weekly during the hospitalization and monthly up to six months after hospital discharge.

  Up to 6 months

Secondary Outcomes (2)

• Collection of stool, oral swabs and blood specimens to define bacterial taxa diversity, microbial translocation as well as metabolomic and proteomic changes associated with the development of graft versus host disease (GvHD)

  Up to 6 months

• GvHD improvement

  Up to 8 weeks after the first dose of FMT

Study Arms (1)

Treatment (OpenBiome FMT capsule DE)

EXPERIMENTAL

Patients ingest OpenBiome FMT Capsule Dose Extended (DE) orally for two consecutive days. One dose is equivalent to the ingestion of 30 capsules and thus each day the patient will ingest 15 capsules. If no response is noted after 7 days, patients may receive a second dose of FMT for an additional 2 days.

Drug: Fecal Microbiota Transplantation Capsule

Interventions

Fecal Microbiota Transplantation Capsule DRUG

Receive OpenBiome FMT Capsule DE PO

Also known as: Fecal Microbiota Preparation Delivery Capsule, FMPCapDE, FMT Capsule DE, FMT Capsule Delivery, FMT DE Capsule

Treatment (OpenBiome FMT capsule DE)

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects who received an allogenic hematopoietic stem cell transplantation (HSCT)
• Acute GvHD defined as experiencing GvHD symptoms starting prior to day +100 after HSCT
• Gut GvHD defined as subjects experiencing GvHD symptoms consistent with stage 3 or stage 4 by Center for International Blood and Marrow Transplant Research (CIBMTR) staging:
• Stage 3 acute gut GvHD subjects having 1500-1999 mL stool per day
• Stage 4 subjects having greater than 2 liters of stool per day and/or severe abdominal cramping, bleeding or ileus
• Steroid-refractory acute gut GVHD defined as progression of symptoms after 3 days of systemic steroids (\> 1 mg/kg/day methylprednisolone) or steroid-resistant acute gut GvHD defined stable symptoms after 5 days of systemic steroids (\> 1 mg/kg/day methylprednisolone)
• Able to swallow capsules without aspiration or dysphagia
• Ability to understand the written informed consent and the willingness to sign the consent and accept the risk of receiving unrelated donor stool

You may not qualify if:

• Absolute neutrophil count \< 500 cells/uL
• Presence of recurrent Clostridium difficile infection
• Presence of ileus or toxic megacolon
• History of multi-drug resistant stool pathogen
• History of inflammatory bowel disease (i.e Crohn's disease or ulcerative colitis)
• Uncontrolled and active systemic infection from bacteria, virus or fungus
• Human immunodeficiency virus (HIV)-positive subjects
• Quantifiable cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV) evaluated by polymerase chain reaction (PCR) after hematopoietic stem cell transplantation (HSCT) and after neutrophil engraftment defined as absolute neutrophil count (ANC) \> 500 cells/uL
• Hemodynamically unstable
• Active gastrointestinal bleed
• Pregnant and/or breastfeeding women
• Dysphagia due to oropharyngeal, esophageal, functional, neuromuscular (e.g. stroke, multiple sclerosis, amyotrophic lateral sclerosis \[ALS\]) or subject shows evidence of dysphagia when the 'safety test' capsule is administered
• Delayed gastric emptying syndrome
• Known chronic aspiration
• Subjects with a history of significant allergy to foods

Sponsors & Collaborators

• Jonsson Comprehensive Cancer Center: lead

Study Sites (1)

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

Location

MeSH Terms

Interventions

Fecal Microbiota Transplantation; Parturition

Intervention Hierarchy (Ancestors)

Biological Therapy; Therapeutics; Pregnancy; Reproduction; Reproductive Physiological Phenomena; Reproductive and Urinary Physiological Phenomena

Study Officials

• Grace Aldrovandi

  UCLA / Jonsson Comprehensive Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 5, 2020
• First Posted: February 21, 2020
• Study Start: September 1, 2023
• Primary Completion: December 30, 2024
• Study Completion: December 1, 2025
• Last Updated: September 22, 2023

Record last verified: 2022-11

Locations

US (1)